Acumen Pharmaceuticals, Inc. SEC filings ABOS
Acumen Pharmaceuticals, Inc. has 365 filings in SEC EDGAR's recent list, going back to May 15, 2013. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 26, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (agreement ended, exit or restructuring costs). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 28, 2026 | — |
| DRS | Filing | Aug 12, 2026 | — |
| EFFECT | Filing | Apr 1, 2026 | — |
| CORRESP | Letter to the SEC | Mar 30, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 30, 2026 | — |
| EFFECT | Filing | Apr 24, 2024 | — |
| CORRESP | Letter to the SEC | Apr 22, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 2, 2024 | — |
| EFFECT | Filing | Jul 8, 2022 | — |
| CORRESP | Letter to the SEC | Jul 6, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 6, 2022 | — |
| SEC STAFF LETTER | Filing | Jun 30, 2021 | — |
| EFFECT | Filing | Jun 30, 2021 | — |
| CERT | Filing | Jun 29, 2021 | — |
| CORRESP | Letter to the SEC | Jun 28, 2021 | — |
| CORRESP | Letter to the SEC | Jun 28, 2021 | — |
| 8-A12B | Filing | Jun 28, 2021 | — |
| CORRESP | Letter to the SEC | Jun 24, 2021 | — |
| CORRESP | Letter to the SEC | Jun 16, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2021 | — |
| CORRESP | Letter to the SEC | Jun 9, 2021 | — |
| SEC STAFF LETTER | Filing | Jun 7, 2021 | — |
| DRS/A | Filing | Jun 3, 2021 | — |
| UPLOAD | Letter from the SEC | May 25, 2021 | — |
| DRSLTR | Filing | May 14, 2021 | — |
| DRS/A | Filing | May 14, 2021 | — |
| UPLOAD | Letter from the SEC | May 10, 2021 | — |
| DRS | Filing | Apr 12, 2021 | — |
| D | Filing | May 15, 2013 | — |
Showing 29 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ABOS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newton, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1576885
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.